Molecular BiologybioRxivPreprint
Pharmacologic METTL3 inhibition attenuates TGF-beta-driven profibrotic signature in systemic sclerosis
Nikolaos I. Vlachogiannis, Simon Tual‐Chalot, Maria Polycarpou‐Schwarz…·Konstantinos Stellos
This study identifies an m6A epitranscriptomic signature in systemic sclerosis that drives profibrotic changes, which can be reversed by METTL3 inhibition.
DOI 10.64898/2026.09.10.750422